The United Kingdom and the United States have hammered out a important bilateral deal that will maintain no levies on UK drug shipments being sold in the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to increase expenditure on drugs through the public health system. This pledge guarantees that tariffs on these vital goods will remain at nothing for a timeframe of 36 months.
This agreement comes after earlier threats to hike import taxes on patented pharmaceutical imports, with potential rates mentioned reaching double the cost.
"This arrangement with the Britain reinforces the global environment for innovative medicines and establishes long-overdue fairness to transatlantic pharmaceutical trade," a release noted.
Commercial Importance
Pharmaceuticals constitute one of the UK's biggest exports to the US, which is easily the primary market for major companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period leading up to September, the UK exported drugs worth £11.1bn to the US. This amount accounted for 17.4% of total UK exports in that period.
"This deal safeguards work, stimulates capital expenditure and facilitates the UK to emerge as a international leader for biotech and pharma," a minister stated.
Detailed British Pledges
The deal includes several specific pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new therapies to be prohibitively costly by 25%.
- Increased NHS Spending: There is a goal to double overall public funding on medicines from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The sum manufacturers must pay back to the NHS to control costs will be capped at 15%. In the past, refunds exceeded 20%.
Industry Background
The pact comes amid a ongoing tension between the sector and the British authorities over medicine costs and NHS adoption.
The disagreement were exacerbated by arguments that American patients were paying several times more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several significant manufacturing plans in the UK have been paused or abandoned, while substantial investments have been directed toward US facilities.
The Science Minister publicly accepted that the NHS had to spend more on medicines, noting that its expenditure on drugs had decreased as a percentage of its total funding over the previous ten-year period.
